Coronavirus disease 2019 vaccines in pregnancy.
Abstract
As of December 1, 2020, nearly 64 million people have been infected with the severe
acute respiratory syndrome coronavirus 2 worldwide with nearly 1.5 million global
deaths. The impact of this virus has continued to overwhelm hospital infrastructure
and demanded remodeling of healthcare systems. With rising concerns for a third, and
possibly the largest, wave of individuals infected with the virus, national leaders
are continuing to seek avenues by which we can further limit disease transmission
and prevent infection with the use of vaccination. To our knowledge, no clinical trial
evaluating vaccines to prevent coronavirus disease 2019 has included pregnant women.
In December 2020, it was anticipated that the Food and Drug Administration will approve
at least 1 or 2 mRNA-based coronavirus disease 2019 vaccine under the Emergency Use
Authorization based on phase 3 clinical trial efficacy data. Both Pfizer and Moderna
have manufactured mRNA-based vaccines with 95% and 94.1% efficacy against the severe
acute respiratory syndrome coronavirus 2. AstraZeneca has manufactured a vaccine using
a viral vector demonstrating early efficacy as well, and this next-generation platform
has previously been utilized with the Ebola vaccine and safely administered during
pregnancy with an acceptable safety profile. Approval of these vaccines will have
a tremendous impact on the ongoing pandemic, yet there remains a lack of data for
use of coronavirus disease 2019 vaccine in pregnant women. In this article, we seek
to discuss the available data regarding treatment and prevention of coronavirus disease
2019 in pregnancy and address the growing questions regarding how best to approach
vaccine access and administration in the pregnant population.
Type
Journal articlePermalink
https://hdl.handle.net/10161/22419Published Version (Please cite this version)
10.1016/j.ajogmf.2020.100295Publication Info
Craig, Amanda M; Hughes, Brenna L; & Swamy, Geeta K (2020). Coronavirus disease 2019 vaccines in pregnancy. American journal of obstetrics & gynecology MFM, 3(2). pp. 100295. 10.1016/j.ajogmf.2020.100295. Retrieved from https://hdl.handle.net/10161/22419.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Amanda Michele Craig
Clinical Associate in the Department of Obstetrics and Gynecology
Brenna L Hughes
Professor of Obstetrics and Gynecology
Geeta Krishna Swamy
Haywood Brown, MD Distinguished Professor of Women's Health
Dr. Geeta Swamy, MD, is Professor of Obstetrics and Gynecology in the Division of
Maternal-Fetal Medicine, having served as the director of the Duke Perinatal Research
Center and Vice Chair for Research and Faculty Development in the Department of ObGyn.
She has achieved international acclaim as a clinician researcher and expert in the
field of maternal immunization and perinatal infection. As a consultant to the World
Health Organization, Dr. Swamy contributes her knowledge to advance inte
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info